Centrum Zdrowia Dziecka I Rodziny Im. Jana Pawla II W Sosnowcu Sp. z o.o.
- Address
- lock Available on a paid plan
Immune System Diseases – Dermatology
The Centrum Zdrowia Dziecka I Rodziny Im. Jana Pawla II in Sosnowiec concentrates on clinical research for immune system diseases that manifest in the skin, with a primary focus on Atopic Dermatitis. The studies aim to assess new therapeutic approaches that could lessen disease severity and enhance patient wellbeing.
- Evaluation of treatment efficacy using standardized severity scores
- Monitoring of safety and tolerability over an extended period
- Assessment of patient‑reported outcomes and quality of life
These investigations strive to deepen understanding of disease mechanisms and bring forward innovative options for long‑term management of skin‑related immune disorders.
Atopic Dermatitis Clinical Trials
The Dermatology department conducts trials involving adolescents with moderate‑to‑severe Atopic Dermatitis. The purpose is to determine whether a novel biologic therapy can more effectively reduce inflammation and improve skin condition compared with existing treatments.
- Measurement of skin clearance using the Eczema Area and Severity Index
- Long‑term follow‑up to evaluate sustained benefit
- Exploration of impact on daily activities and sleep quality
This work complements broader efforts to address immune‑mediated skin diseases and aims to expand therapeutic choices for patients across Poland.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 8 therapeutic areas and 15 of 23 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 11 by active trials.
- 1UCB Biopharma2active
lock +10 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International3trials
lock +6 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centrum Zdrowia Dziecka I Rodziny Im. Jana Pawla II W Sosnowcu Sp. z o.o.
lock Showing 1 of 29 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Ritlecitinib in Adults with Moderate to Severe Hidradenitis Suppurativa | Pfizer Inc. | Phase II | Not Recruiting | Apr 2026 | — |
IMP list
lock Showing 1 of 23 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| (S)-3-(4-Acetamidophenyl)-2-Methoxypropanoic Acid | 2 | Unknown | 2024-11-11 | 2024-11-11 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.